Rapid Molecular Assays for the Diagnosis of Drug-Resistant Tuberculosis [Corrigendum]

Abstract

Nandlal L, Perumal R, Naidoo K. Infect Drug Resist. 2022;15:4971–4984. Table 2 Performance of WHO-Endorsed Molecular Diagnostics for Drug-Resistant TB Diagnosis and Drug-Susceptibility Testing The authors have advised that there is an error in Table 2 on pages 4975 and 4976. The text “$1240” in the Cost Per Test column for the TRUENAT MTB-RIF Dx (Molbio) 2020 row should read “$12.40”. This error was introduced by the Editorial staff during the publication process. The correct Table 2 is shown below.

Keywords

• tuberculosis
• drug-resistance
• molecular assays
• point of care
• diagnosis.